# Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

> **NCT06383884** · PHASE2 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** Patritumab Deruxtecan

## Key facts

- **NCT ID:** NCT06383884
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383884, "Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06383884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*